FDA
-
-
-
-
-
-
-
Kazia files patent for paxalisib strategy in breast cancer
-
-
-
-
-
-
-
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
-
-
-
-
-
-
-
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
-
-
-
-
-
-
-
Kazia plans FDA meeting on glioblastoma drug regulatory pathway
-
-
-
-
-
-
-
Kazia reports paxalisib disrupted cancer cell clusters in lab study
-
-
-
-
-
-
-
Kazia Therapeutics Highlights Recent Progress and Provides Business Update
-
-
-
-
-
-
-
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

